CAN508|cas:140651-18-9|西域试剂

CAN508,99.91%

产品编号：Bellancom-100429| CAS NO：140651-18-9| 分子式：C₉H₁₀N₆O| 分子量：218.22

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100429	￥900.00	杭州北京（现货）
Bellancom-100429	￥1700.00	杭州北京（现货）
Bellancom-100429	￥3500.00	杭州北京（现货）
Bellancom-100429	￥6000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CAN508

产品介绍

CAN508 是一种有效的、ATP 竞争性抑制 CDK9/cyclin T1，IC₅₀为 0.35 μM。CAN508 对 CDK9/cyclin T1 比对其他的 CDK/cyclin 高出 38 倍的选择性。CAN508 具有抗肿瘤活性。

生物活性

CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC₅₀ of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity.

体外研究

CAN508 reduces the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays.
CAN508 (20-40 μM; 72 hours) significantly reduces cell proliferation in a dose dependent manner in all three esophageal adenocarcinoma cell lines (SKGT4, OE33 and FLO-1 cells) with IC₅₀s ranging from 34.99 to 91.09 μM.
CAN508 (40 μM; 72 hours) increases apoptosis in all three esophageal adenocarcinoma cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis

Cell Line:	SKGT4, OE33 and FLO-1 cells
Concentration:	40 μM
Incubation Time:	72 hours
Result:	Increased apoptosis by 2 fold in all three esophageal adenocarcinoma cells compared to untreated controls.

体内研究
(In Vivo)

CAN508 (60 mg/kg; i.p.; daily for 10 days) has antitumor effects in esophageal adenocarcinoma xenografts.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4 weeks-old female nude mice (esophageal adenocarcinoma xenografts)
Dosage:	60 mg/kg
Administration:	I.p.; daily for 10 days
Result:	Caused reduction of tumor growth starting from post-treatment day three with 50.83% reduction.

体内研究

CAN508 (60 mg/kg; i.p.; daily for 10 days) has antitumor effects in esophageal adenocarcinoma xenografts.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4 weeks-old female nude mice (esophageal adenocarcinoma xenografts)
Dosage:	60 mg/kg
Administration:	I.p.; daily for 10 days
Result:	Caused reduction of tumor growth starting from post-treatment day three with 50.83% reduction.

体内研究

CAN508 (60 mg/kg; i.p.; daily for 10 days) has antitumor effects in esophageal adenocarcinoma xenografts.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4 weeks-old female nude mice (esophageal adenocarcinoma xenografts)
Dosage:	60 mg/kg
Administration:	I.p.; daily for 10 days
Result:	Caused reduction of tumor growth starting from post-treatment day three with 50.83% reduction.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (1145.63 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.5825 mL	22.9127 mL	45.8253 mL
5 mM	0.9165 mL	4.5825 mL	9.1651 mL
10 mM	0.4583 mL	2.2913 mL	4.5825 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (9.53 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (9.53 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液